The United States imports approximately 40% [1] of its generic medicines from India, according to U.S. Envoy to India Sergio Gor.
This reliance highlights the strategic importance of the bilateral relationship and the role of Indian manufacturing in maintaining the stability of the American healthcare system. A disruption in this specific supply chain could lead to widespread shortages of affordable medications across the U.S.
Gor said the high share of imports reflects deep trust and a strategic partnership between the two nations. He said that this collaboration strengthens the healthcare supply chain for the United States, ensuring that essential medications remain available to the public.
"We import 40% [1] of our generic medicines from India," Gor said.
The envoy said that the pharmaceutical link is not merely a commercial arrangement but a sign of diplomatic strength. He described the relationship as a critical pillar of the current momentum in U.S.-India ties.
"The deep trust between the United States and India makes Indian pharmaceuticals a life‑saving ingredient for America," Gor said.
By sourcing a significant portion of generics from India, the U.S. maintains access to a wide array of low-cost treatments. This dependency underscores the necessity of continued diplomatic cooperation to ensure regulatory alignment, and steady production flows from Indian facilities to American patients.
“We import 40% of our generic medicines from India.”
The disclosure of this specific import percentage quantifies the U.S. healthcare system's vulnerability to geopolitical shifts in South Asia. By framing this dependency as a product of 'trust' rather than a systemic risk, the U.S. administration is signaling a long-term strategic pivot toward India to diversify supply chains away from other global competitors.
